33670-32-5

Usage

Uses

Used in Organic Synthesis:
MTPB is used as a phase transfer catalyst for facilitating various chemical reactions in organic synthesis. Its ability to transfer reactants between different phases enhances the efficiency and selectivity of the reactions.
Used in Pharmaceutical Synthesis:
MTPB is used as a reagent in the synthesis of pharmaceuticals, contributing to the production of various medicinal compounds. Its catalytic properties aid in the formation of desired products with improved yields and purity.
Used in Electrochemical Energy Storage Devices:
MTPB has been studied for its potential application in electrochemical energy storage devices, such as batteries and supercapacitors. Its unique properties may contribute to improved performance and energy density of these devices.
Used in Antimicrobial Applications:
MTPB has been explored as an antimicrobial agent in some biomedical applications. Its ability to inhibit the growth of certain microorganisms makes it a potential candidate for use in disinfectants and sanitizing products.

Upstream product

• 13057-17-5 bromethyl methyl ether 
• 603-35-0 triphenylphosphine 

Downstream Products

• 6395-78-4 -cyclopropan 
• 6395-75-1 -cyclobutan 
• 110128-40-0 (E)-1-(Phenylsulfonyl)-3-(β-methoxyvinyl)indole 
• 110128-39-7 (Z)-1-(Phenylsulfonyl)-3-(β-methoxyvinyl)indole 
• 251445-09-7 1-(2-methoxyvinyl)-2-(2-propynyloxy)benzene 
• 210173-72-1 1-benzyloxy-2-methoxy-4-(2-methoxyethenyl)benzene 
• 931103-19-4 1-methoxy-2-(3,4,5-trimethoxyphenyl)propene 
• 1039074-75-3 C₇H₁₃NO 
• 136540-80-2 (E)-1-methoxy-2-(2-methoxycarbonylphenyl)ethene 
• 4455-77-0 (methoxymethyl)diphenylphosphine oxide 
• 192947-71-0 Methyl E-α-{2-(1-[4-chlorophenyl]-3-pyrazolyloxy)phenyl}-β-methoxyacrylate 

Relevant academic research and scientific papers

The Preparation and 13C-NMR Spectra of Alkoxymethyl-triphenylphosphonium Salts

Alkoxymethyltriphenylphosphonium salts, X, X: Cl, Br, and I, R: CH3, C2H5, and i-C3H7, have been obtained from the reaction of the triphenylphosphine and the corresponding alkyl halomethyl ether.In the 13C-NMR spectra of these salts, the coupling constant (JCP) is 68-71 Hz, which is larger than that (JCP: 48-56 Hz) of Br,R:H,CH3, and i-C3H7, Me3P=S and Me3P=Se, while it is close to that(66-69Hz) of Me3P=O and Et3P=O.The coupling constant (JCP) of these salts can be caused by the oxygen atom in the salts.

Substituted dienes prepared from betulinic acid – Synthesis, cytotoxicity, mechanism of action, and pharmacological parameters

A set of new substituted dienes were synthesized from betulinic acid by its oxidation to 30-oxobetulinic acid followed by the Wittig reaction. Cytotoxicity of all compounds was tested in vitro in eight cancer cell lines and two noncancer fibroblasts. Almost all dienes were more cytotoxic than betulinic acid. Compounds 4.22, 4.30, 4.33, 4.39 had IC50 below 5 μmol/L; 4.22 and 4.39 were selected for studies of the mechanism of action. Cell cycle analysis revealed an increase in the number of apoptotic cells at 5 × IC50 concentration, where activation of irreversible changes leading to cell death can be expected. Both 4.22 and 4.39 led to the accumulation of cells in the G0/G1 phase with partial inhibition of DNA/RNA synthesis at 1 × IC50 and almost complete inhibition at 5 × IC50. Interestingly, compound 4.39 at 5 × IC50 caused the accumulation of cells in the S phase. Higher concentrations of tested drugs probably inhibit more off-targets than lower concentrations. Mechanisms disrupting cellular metabolism can induce the accumulation of cells in the S phase. Both compounds 4.22 and 4.39 trigger selective apoptosis in cancer cells via intrinsic pathway, which we have demonstrated by changes in the expression of the crucial apoptosis-related protein. Pharmacological parameters of derivative 4.22 were superior to 4.39, therefore 4.22 was the finally selected candidate for the development of anticancer drug.

Visible Light Induced Cyclization to Spirobi[indene] Skeletons from Functionalized Alkylidienecyclopropanes

In this paper, we revealed a metal-free and visible light photoinduced method for the rapid construction of spirobi[indene] skeletons, providing a simple and efficient way for easy access to spirobi[indene] scaffolds under mild conditions along with a broad substrate scope and good functional group tolerance.

4-PHENYLPIPERIDINE DERIVATIVES AS RENIN INHIBITORS

Compounds of the present invention having the formula (I) exhibit inhibitory activity on the natural enzyme renin. Thus, compounds of formula (I) may be employed for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.